FINWIRES · TerminalLIVE
FINWIRES

Barrick Mining Maintained at Buy at Stifel Canada After Q1 Results; Price Target Kept at C$95.00

By

Stifel Canada on Tuesday maintained its buy rating on the shares of Barrick Mining (ABX.TO, B) and its C$95.00 price target following the company's first-quarter results.

"Barrick reported stronger Q1/26 adjusted EPS of $0.98 vs. our $0.75 (consensus $0.81) and adjusted EBITDA of $3.93Bln vs. our $3.38Bln (consensus: $3.26Bln) on attributable gold production of 719Koz vs. our 658Koz and higher vs. Q1/26 guidance of 640-680Koz as well as copper production of 49Kt vs. our 42Kt. Q1/26 total cash cost (TCC) of $1,327/oz vs. our $1,453/oz and AISC of $1,708/oz vs. our $1,904/oz are both tracking at the low-end and below FY26 guidance and Q1/26 consolidated FCF of $1.58Bln vs our $1.14Bln (+38% QoQ) results in FCF/GEO of $1,750 FCF/GEO (+35% QoQ). Barrick reiterated FY26 guidance (incl Q2/26 gold production of 730-770Koz or +4.3% QoQ) and sequential growth through H2/26 driven by the Loulo-Gounkoto ramp-up, Goldrush, Kibali, and NGM. A new $3.0Bln NCIB was authorized over 12 months. We estimate at spot gold and copper prices, the NCIB is 2.0% accretive to our Barrick NAVPS," analyst Ralph Profiti wrote.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $61.81, Change: $-2.59, Percent Change: -4.02%

Related Articles

Research

Research Alert: Integrated Oil & Gas Fundamental Outlook: Neutral, But Reflecting Mixed Views

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:WTI crude oil sits at $101/b today vs. $67/b before U.S. attacks on Iran on February 28, with the Strait of Hormuz largely closed creating an 11-12 mmb/d supply shortage. Independent refiners reported strong Q1 margins, while April CPI hit 3.8%, the highest in three years. We remain neutral on Integrated Oil & Gas, liking downstream but wary of upstream prospects given mixed fundamentals. We estimate WTI averaging $99/b in 2026 but see it falling to $63/b in 2027 due to adverse economic effects on the broader global economy, and UAE departing OPEC, presuming Strait reopening in 2H 2026. We think refining has tailwinds from wider Brent-WTI spreads at $6/b vs. normalized $3.50-$4.00/b and reduced U.S. capacity after two California refinery closures. We anticipate wider refining margins in 2026 and likely into 2027, while most of our upstream EPS estimates are below consensus for 2027.

$XOM
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of George Weston Limited

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain WN at Buy and our target at CAD107, based on our unchanged multiple of 19x our projected FY 27 EPS. We keep our FY 26 EPS estimate at CAD5.10 and FY 27 at CAD5.62. Our rating remains grounded in continued same-store sales (SSS) growth and its best-in-class value offering to the market in a time of affordability issues. WN is reaping the benefits of a stickier inflationary period and plans for nearly half of new stores opened in 2026 to be No Frills or Maxi logos. The company reported Q1 revenue of CAD14,639M, up 4.2% from the prior year. Adjusted net earnings rose 2.9% to CAD349M, while adjusted diluted EPS increased 5.8% to CAD0.91. Loblaw generated revenue of CAD14,484M, up 4.2%, with food retail same-store sales growth of 2.4% and drug retail same-store sales growth of 4.1%. Food sales increased on higher traffic and basket size, with internal food inflation below the 4.4% Consumer Price Index. The discount theme continues to grow as energy ricing remains elevated, stretching the consumer.

$WN
Research

Research Alert: CFRA Retains Buy Rating On Steris Plc

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price at $275, based on 22.7x our new FY 28 EPS forecast, below STE's five-year average forward P/E multiple of 24.2x We keep our FY 27 EPS view at $11.22, which stands above the midpoint of the newly initiated guidance range of $11.10-$11.30, representing a solid 9%-11% Y/Y growth. We start our 2028 EPS estimate at $12.09. STE reported a solid close to its fiscal year 2026, characterized by robust revenue and earnings growth. For FY 26, the company posted a solid 9% Y/Y increase in revenue and adjusted earnings per share grew to $10.17 from $9.22. We expect this solid momentum to carry into FY 27 with 8% Y/Y top-line sales growth amid a more complex operating environment with broad-based growth across the three segments as we see healthy demand. Procedure volumes growth is a key driver for the company, and we see solid growth for the fiscal year ahead, supporting demand for STE's products and services catered for patient care and infection prevention.

$STE